A Risk-Benefit Assessment of Mirtazapine in the Treatment of Depression

被引：0
|
作者：
Siegfried Kasper
Nicole Praschak-Rieder
Johannes Tauscher
Rainer Wolf
机构：
[1] University of Vienna,Department of General Psychiatry
来源：
Drug Safety | 1997年 / 17卷
关键词：
Adis International Limited; Amitriptyline; Sexual Dysfunction; Mirtazapine; Clomipramine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Mirtazapine is the first of a new class of antidepressants, the noradrenergic and specific serotonergic antidepressants (NaSSA). Its antidepressant effect appears to be related to its dual enhancement of central noradrenergic and serotonin 5-HT1 receptor-mediated serotonergic neurotransmission.
引用
收藏
页码：251 / 264
页数：13
相关论文
共 50 条
  • [41] Risk-benefit ratio or risk-benefit nonsense?
    Ernst, E
    Resch, KL
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 1996, 49 (10) : 1203 - 1204
  • [42] THE RISK-BENEFIT ASSESSMENT OF ANTIDEPRESSANT DRUGS
    HENRY, JA
    MARTIN, AJ
    MEDICAL TOXICOLOGY AND ADVERSE DRUG EXPERIENCE, 1987, 2 (06): : 445 - 462
  • [43] A RISK-BENEFIT ASSESSMENT OF TACROLIMUS IN TRANSPLANTATION
    WINKLER, M
    CHRISTIANS, U
    DRUG SAFETY, 1995, 12 (05) : 348 - 357
  • [44] A risk-benefit assessment of abciximab in angioplasty
    Kleiman, NS
    DRUG SAFETY, 1999, 20 (01) : 43 - 57
  • [45] A RISK-BENEFIT ASSESSMENT OF TAMOXIFEN THERAPY
    CATHERINO, WH
    JORDAN, VC
    DRUG SAFETY, 1993, 8 (05) : 381 - 397
  • [46] Clinical equipoise and risk-benefit assessment
    Miller, Franklin G.
    CLINICAL TRIALS, 2012, 9 (05) : 621 - 627
  • [47] A PRELIMINARY RISK-BENEFIT ASSESSMENT OF PACLITAXEL
    BITTON, RJ
    FIGG, WD
    REED, E
    DRUG SAFETY, 1995, 12 (03) : 196 - 208
  • [48] RISK-BENEFIT ASSESSMENT OF CARBAMAZEPINE IN CHILDREN
    SEETHARAM, MN
    PELLOCK, JM
    DRUG SAFETY, 1991, 6 (02) : 148 - 158
  • [49] A risk-benefit assessment of amifostine in cytoprotection
    Mabro, M
    Faivre, S
    Raymond, E
    DRUG SAFETY, 1999, 21 (05) : 367 - 387
  • [50] A risk-benefit assessment of antileukotrienes in asthma
    Smith, LJ
    DRUG SAFETY, 1998, 19 (03) : 205 - 218
12345